☆ 4.8 Letter

Risk of neoplasm with the neurokinin 3 receptor antagonist fezolinetant

LANCET (2023)

Get Full Text
Add to Collection

Journal

LANCET
Volume 402, Issue 10413, Pages 1623-1625

Publisher

ELSEVIER SCIENCE INC
DOI: 10.1016/S0140-6736(23)01634-3

Keywords

-

Categories

Medicine, General & Internal

Ask authors/readers for more resources

Protocol

Community support

Reagent

Community support

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.8
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available
Webinars Posters Questions Hubs Funding Journals Papers Connect Collections Reviewers About Us FAQs Mobile App Privacy Policy Terms of Use
© Peeref 2019-2024. All rights reserved.